What is Opna Bio?
Opna Bio is a specialized biopharmaceutical entity dedicated to the discovery and development of novel oncology therapeutics. Based in Lausanne, the company leverages deep scientific expertise to identify and modulate critical biological targets involved in tumor progression. Its market position is defined by a rigorous focus on precision medicine, aiming to deliver transformative treatments that address significant unmet needs in cancer care. By integrating cutting-edge research with a strategic development roadmap, Opna Bio distinguishes itself as a high-potential player in the global life sciences ecosystem, attracting sophisticated investors who prioritize long-term scientific impact and clinical efficacy.
How much funding has Opna Bio raised?
Opna Bio has raised a total of $38M across 1 funding round:
Series A
$38M
Series A (2022): $38M with participation from Menlo Ventures, Northpond Ventures, and Longitude Capital
Key Investors in Opna Bio
Menlo Ventures
Menlo Ventures is a Menlo Park-based venture capital firm that invests in early and growth-stage technology companies across sectors such as enterprise software, consumer internet, and frontier tech, partnering with founders through multiple stages of scale.
Northpond Ventures
Northpond Ventures is dedicated to advancing science and technology to create significant impacts on humanity, focusing on identifying and supporting breakthrough innovations and entrepreneurial ventures in the scientific landscape.
Longitude Capital
Longitude Capital is a healthcare-focused venture capital firm that invests in biotechnology, medical technology, and health solutions companies, pairing sector expertise and flexible capital to help innovators scale and improve patient care.
What's next for Opna Bio?
With the recent infusion of capital, Opna Bio is poised to scale its research and development operations significantly. The strategic roadmap likely involves the expansion of its internal laboratory capabilities and the advancement of lead candidates through preclinical and early-phase clinical trials. As the company navigates the complexities of drug discovery, the focus will remain on optimizing therapeutic candidates to ensure they meet stringent regulatory and clinical benchmarks. This phase of growth is critical for establishing proof-of-concept, which will be essential for future partnership opportunities or subsequent financing rounds as the company matures into a clinical-stage powerhouse.
See full Opna Bio company page
